Allogeneic CD34+ selected hematopoietic stem cell boost following CAR T‐cell therapy in a patient with prolonged cytopenia and active infection. Issue 3 (24th December 2022)

• Record Type: Journal Article
• Authors: Lipsitt, Amanda; Beattie, Lisa; Harstead, Elaine; Li, Ying; Goorha, Salil; Maron, Gabriela; Gottschalk, Stephen; Triplett, Brandon; Naik, Swati
• Is Part Of: Pediatric blood & cancer. Volume 70:Issue 3(2023)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-12-24
• Subjects: ALL -- BMT -- hematology/oncology; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.30166
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract: Hematological toxicity (hematotoxicity) leading to peripheral cytopenias is a common long‐term adverse effect following the use of CD19‐chimeric antigen receptor (CD19‐CAR) T‐cell therapies. However, management remains unclear for patients whose cytopenias persist beyond 1 month after CAR T‐cell infusion. We present the case of a 21‐year old who received CD19‐CAR T‐cell therapy for relapse following a haploidentical transplant. He developed hematotoxicity and consequently multiple life‐threatening infections. We administered a CD34 + hematopoietic stem cell boost (HSCB) from his transplant donor, which led to hematopoietic recovery and resolution of his infections without any effect on the activity of CD19‐CAR T cells. CD34 + HSCB can be a safe and effective option to treat hematotoxicity following CD19‐CAR T‐cell therapy.